Akebia Therapeutics (AKBA) Expected to Post Earnings on Thursday

Key Points

• Akebia Therapeutics is expected to report Q3 2026 results after the market closes on November 5. Analysts forecast a loss of $0.036 per share and revenue of $46.94 million.
• In its prior quarter, Akebia reported a $0.02 per-share loss, beating the consensus estimate of a $0.04 loss, while revenue reached $49.13 million.
• Analyst sentiment is mixed: four analysts rate the stock Buy, two Hold, and one Sell, producing an overall Hold rating and an average price target of $3.90 versus a recent share price of $0.71.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.0360) per share and revenue of $46.94 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. Akebia Therapeutics had a negative net margin of 13.54% and a negative return on equity of 88.88%. The firm had revenue of $49.13 million for the quarter, compared to the consensus estimate of $48.85 million. On average, analysts expect Akebia Therapeutics to post ($0.14) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Akebia Therapeutics Price Performance

NASDAQ AKBA opened at $0.71 on Friday. Akebia Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.23. The stock's 50-day moving average is $0.85 and its two-hundred day moving average is $1.15. The firm has a market cap of $195.78 million, a P/E ratio of -6.42 and a beta of 0.18. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.43 and a quick ratio of 1.35.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Weiss Ratings lowered Akebia Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 2nd. Leerink Partners lowered Akebia Therapeutics from an "outperform" rating to a "market perform" rating and set a $1.00 target price for the company. in a report on Friday, August 7th. Wall Street Zen lowered Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, October 24th. HC Wainwright reaffirmed a "buy" rating on shares of Akebia Therapeutics in a research report on Thursday, August 6th. Finally, BTIG Research reiterated a "buy" rating and set a $4.00 price target on shares of Akebia Therapeutics in a report on Tuesday, September 15th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $3.90.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company's primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia's key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body's natural production of erythropoietin and support red blood cell formation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.